GO:0019976 interleukin-2 binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019976 (interleukin-2 binding) is a molecular function defined as binding to interleukin-2 (IL-2), a key cytokine in T-cell biology.
• IL-2 binding is mediated by the IL-2 receptor complex, comprising IL-2Rα (CD25), IL-2Rβ (CD122), and IL-2Rγ (CD132), which together confer high-affinity binding and signaling.
• The interaction between IL-2 and its receptor is critical for T-cell proliferation, survival, and effector functions, and is exploited therapeutically in cancer and autoimmune diseases.
• Engineered IL-2 variants and anti-IL-2 antibodies with altered binding properties are being developed to enhance anti-tumor activity while reducing systemic toxicity [2,5].
• CAR T-cell therapies can be augmented by IL-2 binding enhancers that increase CAR T-cell activity and persistence.
• Research on IL-2 binding employs methods such as surface plasmon resonance, flow cytometry, and CRISPR-based gene editing to dissect receptor-ligand interactions [7,8].
Description
Interleukin-2 (IL-2) is a pleiotropic cytokine that plays a central role in the activation, proliferation, and survival of T lymphocytes. The molecular function of interleukin-2 binding (GO:0019976) encompasses the specific interaction between IL-2 and its cell surface receptors, a prerequisite for downstream signaling events that regulate immune responses. This binding event is fundamental to both protective immunity and immune tolerance, and its dysregulation is implicated in autoimmune diseases, immunodeficiency, and cancer. Understanding the molecular details of IL-2 binding is therefore essential for developing targeted immunotherapies. The IL-2 receptor complex is composed of three subunits: the alpha chain (IL-2Rα, CD25), the beta chain (IL-2Rβ, CD122), and the common gamma chain (IL-2Rγ, CD132). While IL-2Rβ and IL-2Rγ alone can bind IL-2 with intermediate affinity, the addition of IL-2Rα creates a high-affinity receptor capable of responding to low physiological concentrations of IL-2. This hierarchical binding mechanism allows for fine-tuned regulation of T-cell responses. Recent advances in protein engineering have led to the development of IL-2 variants with modified binding properties, such as site-specific PEGylation, which preferentially activate regulatory T cells and show promise for treating autoimmune conditions. Similarly, antibodies that block IL-2 binding to the neonatal Fc receptor have been engineered to reduce toxicity while maintaining anti-tumor efficacy. These examples highlight the therapeutic relevance of precisely understanding and manipulating interleukin-2 binding.
interleukin-2 binding At A Glance
| GO ID | GO:0019976 |
|---|---|
| GO term | interleukin-2 binding |
| Ontology | molecular_function |
| Synonym | IL-2 binding |
| Definition | Binding to interleukin-2. |
| Major function | Mediates the interaction between IL-2 and its receptor subunits, initiating signaling. |
| Related genes | IL2RA, IL2RB, IL2RG, IL2, and others. |
| Associated diseases | Autoimmune diseases, cancer, immunodeficiency. |
| Therapeutic relevance | Target for immunosuppressive and immunostimulatory therapies. |
What Is GO:0019976?
According to the Gene Ontology, GO:0019976 (interleukin-2 binding) is defined as the molecular function of binding to interleukin-2. This term describes the selective interaction between a protein or protein complex and the cytokine IL-2, without implying any downstream signaling or biological outcome. It is a child of cytokine binding and is distinct from receptor activity terms that encompass signal transduction.
Why Is interleukin-2 binding Important in Cell Biology?
Interleukin-2 binding is a critical molecular event that governs T-cell homeostasis and immune responses. It is the first step in IL-2 signaling, which controls the balance between effector T-cell expansion and regulatory T-cell suppression. Dysregulated IL-2 binding can lead to autoimmunity or immune evasion by tumors, making it a prime target for therapeutic intervention. For researchers, understanding the structural and kinetic parameters of IL-2 binding is essential for designing biologics that either block or enhance this interaction with precision [2,5].
• IL-2 binding is required for T-cell proliferation and survival, influencing adaptive immunity.
• High-affinity IL-2 binding via the trimeric receptor (IL-2Rαβγ) enables responses to low cytokine concentrations.
• IL-2 binding to regulatory T cells is exploited for immunosuppression in autoimmune diseases.
• Engineered IL-2 variants with altered binding properties can reduce systemic toxicity in cancer therapy.
• IL-2 binding enhancers improve CAR T-cell persistence and anti-tumor activity.
• Mutations in IL-2 receptor subunits that affect binding can cause severe immunodeficiency.
• IL-2 binding is a target for monoclonal antibodies like basiliximab, used to prevent organ transplant rejection.
• Assays measuring IL-2 binding are essential for characterizing cytokine-receptor interactions.
• IL-2 binding modulates the balance between effector and regulatory T cells, impacting autoimmunity and cancer.
• Species-specific differences in IL-2 binding, such as in flounder, reveal evolutionary conservation of immune mechanisms.
Molecular Mechanism of interleukin-2 binding
IL-2 Structure and Receptor Recognition
In simple terms: IL-2 is a small protein that acts like a key, and its receptor is the lock it fits into.
IL-2 is a four-helix bundle cytokine that binds to its receptor through a composite interface involving multiple receptor subunits. The high-affinity receptor consists of IL-2Rα (CD25), IL-2Rβ (CD122), and IL-2Rγ (CD132). IL-2Rα alone binds IL-2 with low affinity, but its association with IL-2Rβ and IL-2Rγ increases affinity by 10- to 100-fold. The binding interface involves residues from the A and B helices of IL-2 and complementary regions on the receptor subunits. Mutational studies have identified critical residues in the IL-2 receptor binding domain that affect ligand-receptor interactions.
Stepwise Assembly of the Receptor Complex
In simple terms: The receptor pieces come together in a specific order to grab IL-2 tightly.
The assembly of the IL-2 receptor complex is a sequential process. IL-2 first binds to IL-2Rα with low affinity, which then recruits IL-2Rβ and IL-2Rγ to form a high-affinity signaling complex. This stepwise assembly allows for fine-tuning of cellular responses based on receptor subunit expression levels. The common gamma chain (IL-2Rγ) is shared among several cytokine receptors, and its involvement in IL-2 binding links IL-2 signaling to broader immune regulatory networks.
Kinetics and Affinity of IL-2 Binding
In simple terms: How fast and how tightly IL-2 sticks to its receptor determines the strength of the signal.
The binding kinetics of IL-2 to its receptor subunits have been characterized using surface plasmon resonance and other biophysical methods. The high-affinity trimeric receptor exhibits a dissociation constant (Kd) in the picomolar range, while the intermediate-affinity dimeric receptor (IL-2Rβγ) has a Kd in the nanomolar range. These differences in affinity are critical for differential responses to IL-2 by effector T cells (intermediate affinity) versus regulatory T cells (high affinity). Engineered IL-2 variants with altered binding kinetics can selectively target specific T-cell subsets.
Regulation of IL-2 Binding by Receptor Expression
In simple terms: Cells can control how much they respond to IL-2 by changing the number of receptors on their surface.
The availability of IL-2 receptor subunits on the cell surface is a major determinant of IL-2 binding capacity. Activation of T cells induces the expression of IL-2Rα (CD25), converting them from intermediate- to high-affinity responders. In contrast, regulatory T cells constitutively express high levels of CD25, allowing them to compete for IL-2 and suppress effector T-cell responses. This dynamic regulation of receptor expression modulates the functional outcomes of IL-2 binding.
Therapeutic Modulation of IL-2 Binding
In simple terms: Scientists are designing drugs that either block or enhance IL-2 binding to treat diseases.
Therapeutic strategies targeting IL-2 binding include monoclonal antibodies that block IL-2Rα (e.g., basiliximab) to prevent T-cell activation in transplantation, and engineered IL-2 variants with site-specific PEGylation that preferentially bind to regulatory T cells for treating autoimmune diseases. Additionally, anti-IL-2 antibodies with reduced neonatal Fc receptor binding have been developed to enhance anti-tumor activity while minimizing toxicity. CAR T-cell therapies can be augmented by IL-2 binding enhancers that increase CAR T-cell persistence.
Key Genes Involved in GO:0019976 interleukin-2 binding
The following genes encode proteins that directly participate in or regulate interleukin-2 binding, including the ligand itself and its receptor subunits.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL2 | Encodes interleukin-2, the ligand that binds to IL-2 receptors. | Central to T-cell growth and immunotherapy. |
| IL2RA | Encodes the alpha subunit of the IL-2 receptor (CD25), conferring high-affinity binding. | Target for immunosuppressive antibodies like basiliximab. |
| IL2RB | Encodes the beta subunit (CD122), shared with IL-15 receptor, essential for signaling. | Determines intermediate-affinity binding and signaling. |
| IL2RG | Encodes the common gamma chain (CD132), shared by multiple cytokine receptors. | Mutations cause X-linked severe combined immunodeficiency. |
| JAK1 | Janus kinase 1, associates with IL-2Rβ and mediates downstream signaling. | Phosphorylates STAT proteins upon IL-2 binding. |
| JAK3 | Janus kinase 3, associates with IL-2Rγ and is critical for signaling. | Mutations lead to immunodeficiency. |
| STAT5A | Signal transducer and activator of transcription 5A, activated by IL-2 binding. | Drives transcription of proliferation genes. |
| STAT5B | Signal transducer and activator of transcription 5B, activated by IL-2 binding. | Regulates T-cell responses. |
| CD4 | Marker of helper T cells that express IL-2 receptors. | Key cell type in IL-2 binding studies. |
| CD8 | Marker of cytotoxic T cells that respond to IL-2. | Effector cells in anti-tumor immunity. |
| FOXP3 | Transcription factor defining regulatory T cells, which express high CD25. | Regulates immunosuppression via IL-2 binding. |
| GSDMD | Gasdermin D, involved in pyroptosis and IL-2 release in CD4+ T cells. | Links inflammasome to IL-2 biology. |
| TCR | T-cell receptor, recognizes antigen and influences IL-2 production. | Context for IL-2 binding in adaptive immunity. |
| PEG | Polyethylene glycol, used to modify IL-2 for extended half-life. | Engineered IL-2 variants for therapy. |
| FcRn | Neonatal Fc receptor, affects antibody half-life and IL-2 antibody design. | Target for reducing systemic toxicity. |
How Is interleukin-2 binding Regulated?
Interleukin-2 binding is regulated at multiple levels. The expression of IL-2 receptor subunits is controlled by transcription factors such as NF-κB and NFAT following T-cell activation. IL-2Rα (CD25) is rapidly induced upon TCR stimulation, while IL-2Rβ and IL-2Rγ are constitutively expressed. Additionally, the availability of IL-2 itself is regulated by its production and consumption. Post-translational modifications, such as glycosylation of IL-2, can affect its binding affinity. Therapeutic interventions, such as PEGylation, can alter binding properties. The binding event is also modulated by the presence of soluble IL-2 receptors or anti-IL-2 antibodies that can sequester the cytokine.
interleukin-2 binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL2RA | Autoimmune diseases, transplant rejection | Knockout mice, human T-cell lines |
| IL2RB | Immunodeficiency, autoimmunity | CRISPR knockout in primary T cells |
| IL2RG | X-linked severe combined immunodeficiency | Patient-derived iPSCs, mouse models |
| IL2 | Cancer, autoimmune diseases | IL-2 knockout mice, tumor models |
| FOXP3 | IPEX syndrome, autoimmunity | Regulatory T-cell-specific knockout |
Interleukin-2 Binding in Autoimmune Diseases
Dysregulated IL-2 binding and signaling contribute to autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis. In these conditions, defective IL-2 production or impaired high-affinity binding can lead to reduced regulatory T-cell function and unchecked effector T-cell activation. Therapeutic strategies that enhance IL-2 binding to regulatory T cells, such as PEGylated IL-2, are being explored to restore immune tolerance.
Interleukin-2 Binding in Cancer
IL-2 binding is critical for anti-tumor immunity, as it promotes the expansion and effector functions of cytotoxic T cells and natural killer cells. High-dose IL-2 therapy has been used in metastatic melanoma and renal cell carcinoma, but severe toxicity limits its use. Engineered IL-2 variants with altered binding properties aim to reduce toxicity while maintaining anti-tumor activity. Additionally, IL-2 binding enhancers can improve CAR T-cell persistence and efficacy.
Interleukin-2 Binding in Immunodeficiency
Mutations in genes encoding IL-2 receptor subunits, such as IL2RG, can abolish IL-2 binding and signaling, leading to severe combined immunodeficiency (SCID). X-linked SCID is caused by mutations in IL2RG, resulting in defective T and NK cell development. Understanding the molecular basis of these mutations provides insights into the structural requirements for IL-2 binding.
From interleukin-2 binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene affect IL-2 binding affinity? | Surface plasmon resonance with recombinant proteins |
| What is the role of a specific IL-2 receptor residue in binding? | Point mutation knock-in in cell lines |
| How does IL-2 binding influence T-cell activation? | CRISPR knockout of IL2RA in primary T cells |
| Can a tagged IL-2 receptor be used for imaging? | Knock-in of fluorescent tag at endogenous locus |
| Does overexpression of IL-2Rα enhance IL-2 binding? | Lentiviral overexpression in T cells |
| What is the effect of IL-2 binding on CAR T-cell persistence? | CAR T cells with IL-2 binding enhancer |
How to Study the interleukin-2 binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Characterizing IL-2-receptor interactions |
| Flow cytometry | Cell surface binding | Measuring IL-2 binding to T-cell subsets |
| Isothermal titration calorimetry | Thermodynamics of binding | Determining enthalpy and entropy changes |
| CRISPR knockout | Loss of binding due to gene disruption | Validating receptor subunit necessity |
| Site-directed mutagenesis | Effect of point mutations on binding | Mapping binding interface residues |
| X-ray crystallography | 3D structure of complex | Visualizing binding interface |
| ELISA | Competitive binding | Quantifying soluble IL-2 or receptor |
Biophysical Methods for Measuring IL-2 Binding
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are used to measure the affinity and kinetics of IL-2 binding to its receptor subunits. These methods provide quantitative parameters such as Kd and kon/koff rates, which are essential for understanding the strength of the interaction.
Cell-Based Binding Assays
Flow cytometry with fluorescently labeled IL-2 can measure binding to cell surface receptors. This approach allows assessment of binding specificity and competition with antibodies or inhibitors. It is widely used to evaluate IL-2 binding to T-cell subsets.
Genetic Approaches to Study IL-2 Binding
CRISPR-Cas9 knockout of IL-2 receptor subunits in cell lines or primary T cells can abolish binding and reveal downstream effects. Point mutations can be introduced to dissect the contribution of specific residues to binding affinity.
Structural Biology of IL-2 Binding
X-ray crystallography and cryo-electron microscopy have provided high-resolution structures of IL-2 in complex with its receptor subunits, revealing the molecular details of the binding interface. These structures guide the design of engineered IL-2 variants with altered binding properties.
How CRISPR Can Be Used to Study GO:0019976 interleukin-2 binding
Knockout
CRISPR knockout of IL2RA, IL2RB, or IL2RG can completely abolish IL-2 binding, providing a clean background to study receptor function. Knockout cell lines are valuable for testing the specificity of IL-2 binding inhibitors and for dissecting signaling pathways.
Point Mutation
Introducing point mutations in the IL-2 binding interface of receptor subunits allows precise mapping of residues critical for binding. For example, mutations in the IL-2 receptor binding domain have been used to study ligand-receptor interactions. CRISPR-based base editing can efficiently create such point mutations.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous IL2RA locus enables real-time imaging and tracking of receptor expression and binding in live cells. This approach preserves physiological regulation of the receptor.
Overexpression
Overexpression of IL-2 receptor subunits via lentiviral transduction can enhance IL-2 binding capacity and amplify downstream signaling. This is useful for studying the effects of increased receptor density on T-cell responses and for engineering cells with enhanced cytokine sensitivity.
How EDITGENE Supports interleukin-2 binding Research
Researchers studying interleukin-2 binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling rigorous functional studies of IL-2 binding and its role in health and disease.
Contact EDITGENE today to design your custom CRISPR model for interleukin-2 binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IL2RA Knockout HEK293 Cell Line | EDJ-KQ493 | Human | 3559 | Details Get a Quote |
| IL2RB Knockout HEK293 Cell Line | EDJ-KQ494 | Human | 3560 | Details Get a Quote |
| IL2RG Knockout HEK293 Cell Line | EDJ-KQ495 | Human | 3561 | Details Get a Quote |
| IL2RA Knockout HeLa Cell Line | EDJ-KQ53631 | Human | 3559 | Details Get a Quote |
| IL2RB Knockout HeLa Cell Line | EDJ-KQ53632 | Human | 3560 | Details Get a Quote |
| IL2RG Knockout HeLa Cell Line | EDJ-KQ53633 | Human | 3561 | Details Get a Quote |
| IL2RA Knockout A-549 Cell Line | EDJ-KQ62106 | Human | 3559 | Details Get a Quote |
| IL2RB Knockout A-549 Cell Line | EDJ-KQ62107 | Human | 3560 | Details Get a Quote |
| IL2RG Knockout A-549 Cell Line | EDJ-KQ62108 | Human | 3561 | Details Get a Quote |
| IL2RA Knockout HCT 116 Cell Line | EDJ-KQ70593 | Human | 3559 | Details Get a Quote |
| IL2RB Knockout HCT 116 Cell Line | EDJ-KQ70594 | Human | 3560 | Details Get a Quote |
| IL2RG Knockout HCT 116 Cell Line | EDJ-KQ70595 | Human | 3561 | Details Get a Quote |
Displaying Records 1 To 12 Of 12 Records
Frequently Asked Questions About interleukin-2 binding
What is interleukin-2 binding?
Interleukin-2 binding (GO:0019976) is the molecular function of selectively interacting with the cytokine interleukin-2 (IL-2), typically mediated by the IL-2 receptor complex on the cell surface.
What genes are involved in interleukin-2 binding?
Key genes include IL2 (encoding the ligand), IL2RA, IL2RB, and IL2RG (encoding receptor subunits), as well as downstream signaling molecules like JAK1, JAK3, and STAT5.
What is the GO ID for interleukin-2 binding?
The Gene Ontology ID for interleukin-2 binding is GO:0019976.
How does interleukin-2 binding affect T cells?
IL-2 binding promotes T-cell proliferation, survival, and effector functions, and is essential for both protective immunity and immune tolerance.
What diseases are associated with defects in interleukin-2 binding?
Defects can lead to severe combined immunodeficiency (e.g., IL2RG mutations), autoimmune diseases due to impaired regulatory T-cell function, and cancer due to immune evasion [4,8].
How is interleukin-2 binding measured experimentally?
Common methods include surface plasmon resonance, flow cytometry, and isothermal titration calorimetry to determine binding affinity and kinetics.
Can interleukin-2 binding be targeted therapeutically?
Yes, therapeutic strategies include blocking antibodies (e.g., basiliximab) for transplantation, and engineered IL-2 variants for cancer immunotherapy and autoimmune diseases [1,2,5].
What is the role of IL-2Rα in interleukin-2 binding?
IL-2Rα (CD25) confers high-affinity binding to IL-2 when associated with IL-2Rβ and IL-2Rγ, allowing responses to low cytokine concentrations.
How do CRISPR models help study interleukin-2 binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of the genes and residues involved in IL-2 binding and downstream signaling.
What are the latest advances in interleukin-2 binding research?
Recent advances include site-specific PEGylation of IL-2 for sustained regulatory T-cell activation, anti-IL-2 antibodies with reduced FcRn binding for cancer therapy, and CAR T-cell enhancers that boost IL-2 binding [2,5,6].
Conclusion
Interleukin-2 binding (GO:0019976) is a fundamental molecular function that underpins T-cell immunity and tolerance. Its precise regulation and structural determinants are critical for understanding immune responses and for developing next-generation immunotherapies. By leveraging CRISPR-based models and advanced biophysical assays, researchers can continue to unravel the complexities of IL-2 binding and translate these insights into clinical applications.
References
- 1. Onrust SV et al.. 1999. Basiliximab.. Drugs 57(2):207-13; discussion 214 PMID: 10188761
- 2. Zhang B et al.. 2021. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells.. Nat Biomed Eng 5(11):1288-1305 PMID: 34580438
- 4. Orozco Valencia A et al.. 2020. Interleukin-2 as immunotherapeutic in the autoimmune diseases.. Int Immunopharmacol 81:106296 PMID: 32058934
- 5. Lv Y et al.. 2025. An antibody against human interleukin-2 showing minimal binding to neonatal Fc receptor: Potent anti-tumor activity and reduced systemic toxicity in mice.. Eur J Pharmacol 987:177159 PMID: 39615864
- 6. Rakhshandehroo T et al.. 2025. A CAR enhancer increases the activity and persistence of CAR T cells.. Nat Biotechnol 43(6):948-959 PMID: 39079964
- 7. vanderSpek JC et al.. 1996. DAB389 interleukin-2 receptor binding domain mutations. Cytotoxic probes for studies of ligand-receptor interactions.. J Biol Chem 271(21):12145-9 PMID: 8647806
- 8. Zhao M et al.. 2022. Expression of Interleukin-2 receptor subunit gamma (IL-2Rγ) and its binding with IL-2 induced activation of CD4 T lymphocytes in flounder (Paralichthys olivaceus).. Fish Shellfish Immunol 122:426-436 PMID: 35183740
